One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Progyny logo
Progyny PGNY
$ 35.72 0.7%
report update icon

Quarterly report 2026-Q3
added 11-05-2026

Progyny Financial Ratios 2025-2011 | PGNY

Brief overview of Progyny's valuation multiples

Current figures are compared with the company's own five-year history for 2021–2025.

The latest available valuation ratios are P/E 31.61x (median 56.08x), EV/EBITDA 97.36x (median 99.76x), P/S 5.81x (median 5.81x). Valuation is roughly 43% below five-year reference levels. The discount may reflect opportunity or higher perceived risk.

At the current P/E, inverse earnings yield is 3.2%, a useful bridge between price and business earnings.

Current measures of operating quality are ROE 11.3%, ROA 7.9%, ROCE 2.9%. Capital returns look adequate and support overall financial resilience.

PEG of 0.56x shows valuation is not outpacing embedded growth. The conclusion depends on earnings durability.

The cash conversion cycle increased 68.2 days to 95.5 days, weakening working-capital efficiency.

Conclusion

Progyny's high-quality returns come with historically restrained multiples. Price appears more cautious than current business efficiency.

Annual Financial Ratios Progyny

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
31.6 34.4 56.1 115.8 68.2 78.2 -69.4 - - - - - - - -

P/S

5.8 6.3 3.2 4.5 9.0 10.5 2.6 - - - - - - - -

EPS

0.1 0.1 0.7 0.3 0.7 0.5 -0.4 0.0 -2.4 - - - - - -

EV (Enterprise Value)

1.96 B 1.89 B 3.58 B 3.56 B 4.5 B 3.65 B 551 M 30.2 M 24.3 M - - - - - -

EBITDA per Share

0.24 0.22 0.68 0.27 0.38 0.12 0.57 - - - - - - - -

EV/EBITDA

97.4 99.8 55.6 142.7 133.8 356.0 43.6 - - - - - - - -

PEG

0.56 0.89 - - - 0.13 0.17 - - - - - - - -

P/B

3.6 4.4 6.3 9.3 17.8 21.8 5.2 - - - - - - - -

P/CF

8.8 10.4 18.4 43.7 172.3 100.4 -132.5 - - - - - - - -

ROE %

11.34 12.87 11.21 8.05 26.12 27.83 -7.50 - - - - - - - -

ROA %

7.88 8.95 8.20 5.59 18.37 18.30 -5.70 - - - - - - - -

ROCE %

2.82 3.60 10.90 6.09 12.47 4.74 8.47 - - - - - - - -

Current Ratio

3.3 3.3 3.7 3.3 3.4 2.9 3.7 - - - - - - - -

DSO

261.1 291.8 80.8 86.9 76.6 64.9 74.8 - - - - - - - -

DPO

165.6 171.3 50.4 50.3 49.3 41.8 38.4 - - - - - - - -

Operating Cycle

- - - - - - 74.8 - - - - - - - -

Cash Conversion Cycle

- - - - - - 36.4 - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Progyny

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

0.34 0.36 0.3 0.15 0.16 0.2 0.18 0.12 0.12 0.18 0.18 0.14 0.17 0.16 0.19 0.04 0.14 0.1 0.05 0.17 0.19 0.21 0.17 0.45 0.06 -0.01 0.04 -0.07 -1.1 - 0.01 -0.3 -0.2 -0.22 0.73 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

0.46 0.53 0.46 0.15 0.27 0.3 0.3 0.18 0.15 0.22 0.2 0.13 0.2 0.17 0.17 0.03 0.13 0.1 - -0.01 0.1 0.14 0.14 0.01 0.06 -0.01 0.05 0.02 0.62 0.66 0.24 -0.14 0.14 -0.06 -0.32 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

20.46 16.60 13.73 11.44 11.52 11.44 11.73 11.46 11.40 12.09 11.67 12.88 11.35 12.07 11.70 9.31 14.39 18.08 24.42 30.85 48.27 44.60 34.55 29.38 2.12 -8.89 -6.67 -7.50 -2.05 6.33 5.90 1.60 1.19 0.90 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

12.95 10.81 9.14 7.74 7.79 7.62 7.74 7.45 7.91 8.53 6.17 8.89 7.74 8.14 7.83 6.31 9.89 12.29 16.40 20.35 31.52 28.92 22.32 19.19 0.88 -6.97 -5.36 -5.70 -6.46 -3.75 1.68 -3.69 -2.75 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

26.95 22.56 18.65 15.91 16.69 15.77 15.63 13.97 12.79 13.44 12.18 12.33 10.78 10.55 10.21 6.80 5.87 6.59 9.28 15.40 16.13 16.04 9.67 6.45 6.79 5.66 8.62 8.47 8.21 6.14 4.42 0.74 0.62 0.34 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

2.6 2.7 2.7 3.3 3.4 3.1 2.8 3.3 2.9 2.9 - 3.7 3.4 3.2 2.9 3.3 3.1 3.0 3.1 3.4 3.0 2.9 2.7 2.9 2.7 3.1 3.0 4.2 4.2 4.2 4.2 1.4 1.4 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

67.7 67.8 67.2 67.8 76.3 78.3 75.3 78.9 91.5 44.1 39.7 86.3 86.7 94.4 97.7 106.0 108.4 100.1 88.1 96.5 103.0 91.3 71.8 70.0 66.1 92.4 63.6 65.9 70.2 76.5 68.0 72.9 38.3 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DPO

53.2 54.1 52.4 46.7 50.0 51.4 44.3 43.8 56.6 29.4 26.5 55.1 54.8 57.5 58.2 57.3 56.3 53.5 47.9 52.0 53.6 51.6 49.3 49.1 43.3 61.9 41.7 33.2 36.2 39.6 42.9 59.8 31.2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

- - - - - - - - - - - - - - - - - - - - - - - - - - - 65.9 70.2 76.5 68.0 72.9 38.3 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

- - - - - - - - - - - - - - - - - - - - - - - - - - - 32.8 34.0 36.9 25.2 13.1 7.0 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Progyny, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Health information services industry

Issuer Price % 24h Market Cap Country
Schrödinger Schrödinger
SDGR
$ 22.92 -12.98 % $ 1.68 B usaUSA
So-Young International So-Young International
SY
$ 1.66 -11.97 % $ 129 M chinaChina
SCWorx Corp. SCWorx Corp.
WORX
$ 1.08 -5.18 % $ 7.86 M usaUSA
Zhongchao Zhongchao
ZCMD
$ 0.78 -3.79 % $ 2.67 M chinaChina
Teladoc Health Teladoc Health
TDOC
$ 7.47 -4.29 % $ 1.32 B usaUSA
Computer Programs and Systems Computer Programs and Systems
CPSI
- 4.4 % $ 133 M usaUSA
Phreesia Phreesia
PHR
$ 11.41 -4.0 % $ 682 M usaUSA
Akerna Corp. Akerna Corp.
KERN
- - $ 161 M usaUSA
MTBC MTBC
MTBC
- -0.58 % $ 51.7 M usaUSA
Premier Premier
PINC
- - $ 2.33 B usaUSA
Streamline Health Solutions Streamline Health Solutions
STRM
- - $ 21.4 M usaUSA
1Life Healthcare 1Life Healthcare
ONEM
- - $ 3.37 B usaUSA
NantHealth NantHealth
NH
- -46.64 % $ 10.4 M usaUSA
Change Healthcare Change Healthcare
CHNG
- - $ 9.03 B usaUSA
Covetrus Covetrus
CVET
- - $ 2.94 B usaUSA
R1 RCM R1 RCM
RCM
- - $ 3.81 B usaUSA
Tabula Rasa HealthCare Tabula Rasa HealthCare
TRHC
- - $ 255 M usaUSA
Cerner Corporation Cerner Corporation
CERN
- - $ 27.9 B usaUSA
Accolade Accolade
ACCD
- 0.29 % $ 206 M usaUSA
Signify Health Signify Health
SGFY
- -0.02 % $ 7.21 B usaUSA
Allscripts Healthcare Solutions Allscripts Healthcare Solutions
MDRX
- -10.39 % $ 886 M usaUSA
NextGen Healthcare NextGen Healthcare
NXGN
- - $ 1.6 B usaUSA
iCAD iCAD
ICAD
- - $ 102 M usaUSA
OptimizeRx Corporation OptimizeRx Corporation
OPRX
$ 6.63 -5.42 % $ 123 M usaUSA
HealthStream HealthStream
HSTM
$ 26.18 0.15 % $ 786 M usaUSA
American Well Corporation American Well Corporation
AMWL
$ 10.75 0.28 % $ 173 M usaUSA
Evolent Health Evolent Health
EVH
$ 3.9 14.01 % $ 445 M usaUSA
GoodRx Holdings GoodRx Holdings
GDRX
$ 2.91 -3.64 % $ 1.04 B usaUSA
Castlight Health, Inc. Castlight Health, Inc.
CSLT
- -7.28 % $ 227 M usaUSA
HMS Holdings Corp. HMS Holdings Corp.
HMSY
- - $ 3.29 B usaUSA
Inovalon Holdings, Inc. Inovalon Holdings, Inc.
INOV
- - $ 6.37 B usaUSA
Health Catalyst Health Catalyst
HCAT
$ 1.32 2.33 % $ 92.3 M usaUSA
HealthEquity HealthEquity
HQY
$ 94.7 -2.75 % $ 8.16 B usaUSA
Omnicell Omnicell
OMCL
$ 32.36 -2.47 % $ 1.49 B usaUSA
Veeva Systems Veeva Systems
VEEV
$ 266.16 1.18 % $ 43.6 B usaUSA
10x Genomics 10x Genomics
TXG
$ 51.71 -9.89 % $ 6.45 B usaUSA